Expand TAK Menu
TAK MENU

TAK Latest Press Releases

-- April 26, 2024 --

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Business Wire 8:30 AM

-- April 23, 2024 --

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PRNewswire 7:00 AM

-- April 22, 2024 --

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PRNewswire 4:10 AM

-- April 18, 2024 --

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease Business Wire 7:00 PM

-- April 8, 2024 --

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food Business Wire 8:00 AM

-- March 27, 2024 --

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PRNewswire 8:53 AM

-- March 26, 2024 --

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting Business Wire 7:07 PM
Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Business Wire 8:00 AM

-- March 19, 2024 --

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL Business Wire 12:20 PM
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders Globe Newswire 6:30 AM

-- March 13, 2024 --

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia Business Wire 8:00 AM

-- February 26, 2024 --

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas Business Wire 11:30 PM

-- February 12, 2024 --

FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) Business Wire 8:00 AM

-- February 8, 2024 --

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024 Business Wire 6:00 PM

-- February 1, 2024 --

Takeda Announces Chief Financial Officer Succession Business Wire 1:54 AM
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products Business Wire 1:02 AM

-- January 31, 2024 --

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset ACCESSWIRE 4:07 PM

-- January 29, 2024 --

Takeda's GAMMAGARD LIQUID Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business Wire 11:10 AM
Takeda's HYQVIA Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business Wire 2:00 AM

-- January 25, 2024 --

Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation PRNewswire 5:00 PM

-- January 18, 2024 --

Takeda Named Global Top Employer for Seventh Consecutive Year Business Wire 7:00 AM

-- January 16, 2024 --

U.S. FDA Approves Takeda's HYQVIA as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business Wire 8:00 AM

-- December 21, 2023 --

Takeda Announces China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies Business Wire 4:00 PM

-- December 15, 2023 --

Takeda Receives Positive CHMP Opinion for HYQVIA as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business Wire 8:16 AM

-- December 5, 2023 --

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners Business Wire 8:00 AM